# Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy

## TL;DR

This study evaluates how often breast cancer patients achieve a complete response after neoadjuvant therapy and finds factors linked to better outcomes.

## Contribution

The study identifies specific treatment regimens and tumor markers associated with higher pathological complete response rates in breast cancer patients.

## Key findings

- 21.6% of patients achieved a pathological complete response (pCR) after neoadjuvant therapy.
- The AC-TH regimen and HER2-positive tumors were significantly associated with higher pCR rates.
- pCR was linked to improved disease-free survival in breast cancer patients.

## Abstract

This study aims to assess the rate of pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant therapy and to explore its correlation with clinical, molecular, and prognostic factors.

We conducted this retrospective observational study at Liga Contra o Câncer, a major public oncology reference center in Northeast Brazil. We included patients diagnosed with breast cancer who initiated neoadjuvant therapy between June 2018 and June 2019. Patients with a history of recurrent breast cancer or those who did not undergo surgery were excluded. The primary outcome was the pCR rate, with secondary outcomes including Overall Survival (OS), Disease-Free Survival (DFS), mortality, and disease recurrence. Follow-up extended until August 2022. We performed multivariate Cox regression analysis to correlate outcomes with predetermined variables.

Of the 292 included patients, 63 (21.6%) achieved pCR. The mean follow-up duration was 42.8 months. Multivariate logistic regression analysis revealed an association between pCR and the AC-TH regimen [OR = 2.4; 95%CI = 1.13 - 5.24; p=0.023], as well as between pCR and HER2-positive tumors [OR 2.49; 95% CI = 1.14 - 5.86; p=0.028]. Complete pathological response was associated with higher DFS [HR 0.33; 95%CI 0.13-0.86; p=0.024].

Neoadjuvant therapy demonstrated significant efficacy in achieving pathological response in breast cancer patients. We observed a strong association between the AC-TH regimen, HER2-positive status, and pCR.